Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02526 德適－Ｂ
DIAGENS-B
Listing Date2026/03/30    Listing in 2 Days
Listing Price99.000
Grey Market Performance
Last updated: 27/03/2026 19:59  Refresh
  • Bright Smart
    up 192.700 +93.700 (+94.646%)
    High
    200.000
     
    Low
    130.000
    Volume
    16,200
    One Lot Profit
    +4,685.00
  • Phillip
    up 193.600 +94.600 (+95.556%)
    High
    205.000
     
    Low
    140.000
    Volume
    404,000
    One Lot Profit
    +4,730.00
  • Futu
    up 199.500 +100.500 (+101.515%)
    High
    208.000
     
    Low
    150.000
    Volume
    558,700
    One Lot Profit
    +5,025.00
  • Bid
  • Ask
  • 192.700
  • (1) 250
  • 50 (1)
  • 193.800
  • 192.600
  • (0) 0
  • 0 (0)
  • 193.900
  • 192.500
  • (0) 0
  • 0 (0)
  • 194.000
  • 192.400
  • (0) 0
  • 0 (0)
  • 194.100
  • 192.300
  • (0) 0
  • 0 (0)
  • 194.200
  • 192.200
  • (0) 0
  • 0 (0)
  • 194.300
  • 192.100
  • (0) 0
  • 0 (0)
  • 194.400
  • 192.000
  • (0) 0
  • 0 (0)
  • 194.500
  • 191.900
  • (0) 0
  • 50 (1)
  • 194.600
  • 191.800
  • (2) 150
  • 0 (0)
  • 194.700
  • Bid
  • Ask
  • 193.100
  • (1) 100
  • 450 (1)
  • 193.600
  •  
  • (4) 1.65K
  • 0 (0)
  •  
  •  
  • (0) 0
  • 0 (0)
  •  
  •  
  • (0) 0
  • 0 (0)
  •  
  •  
  • (0) 0
  • 550 (2)
  •  
 
Hide
Subscription Result
  • Subscription Rate
    1,073.37x
  • Guarantee One Lot Size
    1400 lot
  • One Lot Success Rate
    3%
COMPANY PROFILE

Hangzhou Diagens Biotechnology Co. was established in 2016, it is a medical device company focusing on developing medical imaging products and services. The Group has self-developed a diversified portfolio, which comprises: six medical imaging software products, including its Core Product, AI AutoVision®, which is at the registration stage, one commercialized product, AutoVision®, as well as four pre-clinical stage product candidates; three commercialized medical devices; and four key reagents and consumables.

--

The Group’s Core Product, AI AutoVision®, is an auxiliary diagnostic software designed to undertake intelligent analysis on chromosome karyotyping. The Group has initially established a nationwide distribution network of 75 distributors, successfully covering over 400 healthcare centers and medical institutions in 31 provinces, autonomous regions and municipalities as of September 30, 2025.

--

As of March 10, 2026, the Group has established one production facility located in Hangzhou, Zhejiang Province, namely the Smart Health Valley Production Base, with 18 manufacturing personnel and a total of four production lines, all of which focus on manufacturing medical devices and medical imaging software, with annual designed production capacity of 2,000 units.

--

The Group’s customers are primarily distributors, hospitals, digital infrastructure service providers, medical institutions, research organizations and third-party medical laboratories.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot50
GLOBAL OFFERING
No. of Offer Shares8.00M H shares
No. of International Offer Shares7.20M H shares
No. of HK Offer Shares0.80M H shares
Offer Price$95.60 - $112.50
Stock Code2526
Sponsor(s)Huatai Financial Holdings (Hong Kong) Limited
Underwriter(s)Huatai Financial Holdings (Hong Kong) Limited, Futu Securities International (Hong Kong) Limited, ABCI Securities Company Limited, BOCI Asia Limited, CCB International Capital Limited, China Galaxy International Securities (Hong Kong) Co., Limited, Huafu International Securities Limited, Yellow River Securities Limited, Yuen Meta (International) Securities Limited, Yunfeng Securities Limited, Zheshang International Financial Holdings Co., Limited
TIME TABLE
Application PeriodMar 20 (Fri) - noon, Mar 25 (Wed)
Price Determination DateMar 26 (Thu)
Result Announcement DateOn or before Mar 27 (Fri)
Result Announcement DateOn or before Mar 27 (Fri)
Result Announcement DateOn or before Mar 30 (Mon)
Dealings in Shares commence onMar 30, 2026. (Mon)
Reallocation of Shares Offered
Sales Statistics (HKD)
Offer Price$95.60 - $112.50
Capitalization (H Shares)8.50B - 10.00B
NAV / share ($)$10.57 - $12.03 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 104.1, the net proceeds raised would be HKD 762.90M, of which
49% : Development and commercialization of Core Product AI AutoVision®
10% : Research and development of other medical imaging software product candidates and medical devices
20% : Enhance iMedImage® foundation model and AI technologies as well as to strengthen technology licensing business
8% : Strengthen commercialization capabilities and market penetration in China
5% : Expand presence in global markets
8% : Pursue strategic collaboration and investment opportunities
IPO NEWS
27/03/2026 18:35
{New Stock}DIAGENS-B(02526) ends up 95.56% on grey market
27/03/2026 16:20
{New Stock}DIAGENS-B up 85.35% at HK$183.5 on grey market
Related Document
Prospectus Prospectus  Chinese VersionProspectus  English Version
Remark： The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
 :
Subscribing Lot :
Subscribing Fee :
Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2026 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.